Core Viewpoint - The announcement details the completion of additional share pledges by the controlling shareholder of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., aimed at securing a bond issuance, with significant implications for the company's financial stability and shareholder structure [1][2]. Group 1: Share Pledge Details - As of February 5, 2026, the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 523,231,148 shares, representing 55.60% of the total share capital, with 421,115,848 shares pledged, accounting for 80.48% of its holdings [2][4]. - The controlling shareholder has pledged an additional 1,170,000 shares to secure the 23 Chuang 02EB bond, with the pledge completed on February 6, 2026 [3][4]. - The total number of pledged shares has decreased due to a bond conversion, with the previous pledge count adjusted accordingly [4]. Group 2: Financial Health and Risk Assessment - The controlling shareholder has no significant litigation or arbitration issues related to debt, and its operational and performance status is normal, with debt repayment sources identified [9][10]. - The controlling shareholder's total outstanding exchangeable bonds amount to 427.25 million yuan, with no immediate repayment risks identified [9]. - The company assesses that the current pledge situation does not pose a risk of forced liquidation or transfer, and the controlling shareholder is expected to take proactive measures if necessary [10].